To select innovative drug candidates to enter the development phase

The company is developing other drug candidates targeting new receptors of interest in immuno-oncology, autoimmune/inflammatory diseases, and transplantion, using monoclonal or bispecific antibodies.

Agonist or antagonist products of the immune response which are obtained will enable the restoration of immune disorders and could be evaluated alone or in combination.

Other checkpoint inhibitors or immunomodulators could also be selected and optimized and, supported by R&D proof of concept, enter into clinical phase.